McKesson Corporation
Healthcare Distribution and TechnologyFounded 1833- Updated June 2025
Reviewed by Swet Parvadiya
Last reviewed: June 2025
CorpDigest
McKesson Corporation
Company History
Founded 1833 in Irving, Texas
Last reviewed: 2025-06-08 · By Swet Parvadiya
Olcott and McKesson opened their pharmaceutical wholesale business on Maiden Lane in New York City in 1833. The American pharmaceutical industry barely existed. Most drugs were compounded by individual apothecaries from raw materials. The wholesaler's function — aggregating supply from producers and distributing it to retail dispensers — was genuinely new, and it created the structural template that still defines the pharmaceutical distribution industry 190 years later.
The company expanded into chemical pharmaceuticals in the 1850s as the modern pharmaceutical industry began to take shape around synthetic compounds and standardized dosage forms. By 1989, when McKesson completed its IPO, it was operating one of the largest pharmaceutical distribution networks in the United States, with the institutional relationships and logistics infrastructure that smaller competitors could not replicate.
The 2001 acquisition of RelayHealth added software-based healthcare connectivity — electronic prescribing, pharmacy management tools — that extended McKesson's reach beyond physical distribution into the information layer of pharmaceutical dispensing. The 2010 acquisition of US Oncology, which managed a network of community cancer care practices, pushed McKesson into specialty pharmacy and oncology care management, categories where margins are significantly higher than general pharmaceutical distribution.
The Change Healthcare joint venture, formed in 2013 and converted to full ownership in 2024, brought McKesson into healthcare claims processing and revenue cycle management at scale. That acquisition — and the cyberattack that disrupted it in its first months under full McKesson ownership — defined the company's FY2024 story more than any operational metric.
Charles A. McKesson was a young Irish immigrant with a keen eye for commerce who recognized that the emerging field of botanical medicine held the potential to revolutionize the treatment of human disease. His decision to co-found Olcott & McKesson in 1833 was driven by the explicit goal of applying industrial distribution principles to the production of botanical drugs, ensuring that every batch contained a precise, standardized dose of the active compound. This focus on standardization was not merely a quality control measure; it was a revolutionary business strategy that allowed the company to build brand trust, scale production, and establish a distribution network that would eventually span the globe. McKesson's shrewd commercial acumen and his willingness to invest heavily in proprietary distribution processes allowed the young company to carve out a niche in the growing market for high-quality botanical drugs, despite intense competition from established chemical manufacturers. His leadership laid the groundwork for the company's subsequent pivot to the industrial distribution of chemical pharmaceuticals in the mid-19th century, a move that would transform the company into a global healthcare distribution powerhouse and generate the massive cash flows that funded its entry into the healthcare technology and specialty patient services markets. McKesson's legacy is defined by his understanding that the future of healthcare lay in bringing scientific rigor and industrial efficiency to the business of human health, a philosophy that remains the bedrock of the organization's operations today.
Charles A. McKesson and John Olcott founded Olcott & McKesson in New York City, with the explicit vision of importing and wholesaling high-quality botanical drugs and chemicals to the burgeoning American medical market, establishing the foundational business model of scalable, reliable physical distribution.
The organization made the strategic decision to pivot from pure botanical importation to the industrial distribution of chemical pharmaceuticals and surgical instruments, a move that would fundamentally alter the trajectory of the company and establish its dominance in the global healthcare distribution market.
McKesson completed its initial public offering, raising significant capital to fund the expansion of its global distribution footprint and the acceleration of its R&D pipeline in healthcare technology.
The organization acquired RelayHealth, securing exclusive rights to the pharmacy connectivity and patient adherence platform, positioning the company at the forefront of the next-generation healthcare technology market.
The organization entered into a strategic joint venture with CVS Health to form Change Healthcare, securing exclusive rights to the medical claims clearinghouse and revenue cycle management platform.
The organization finalized a historic $13.8 billion opioid litigation settlement spanning 18 years, resolving a decade of legal challenges and allowing the company to focus on its core business operations and technology development.
The organization completed the $13.8 billion full acquisition of Change Healthcare, securing full ownership of the medical claims clearinghouse and revenue cycle management platform, and integrating Change Healthcare's world-class healthcare IT research capabilities directly into its global R&D pipeline.
The organization reported consolidated net revenues of $308.9 billion for FY2024, with the Pharmaceutical Distribution & Retail Support division contributing the vast majority of this total through the sale of high-margin biologics, small molecules, and targeted therapies, while allocating approximately $1.0 billion to research and development.
The organization faced a catastrophic February 2024 cyberattack on the Change Healthcare network, temporarily paralyzing medical billing for thousands of US hospitals and forcing the company to inject over $1.5 billion in advanced liquidity payments to providers.
The organization announced the integration of advanced artificial intelligence algorithms into its revenue cycle management workflows, aiming to automate the scrubbing of medical claims and identify novel predictive analytics models, further solidifying its leadership in the healthcare IT market.
The organization completed the full acquisition of Change Healthcare for $13.8 billion to secure full ownership of the medical claims clearinghouse and revenue cycle management platform, and to integrate Change Healthcare's world-class healthcare IT research capabilities directly into its global R&D pipeline.
The organization acquired RelayHealth for $1.2 billion to secure exclusive rights to the pharmacy connectivity and patient adherence platform, positioning the company at the forefront of the next-generation healthcare technology market.
The organization acquired US Oncology for $2.0 billion to establish its leadership in the community oncology market, securing exclusive rights to a massive network of affiliated physicians and clinical trial sites.
Charles A. McKesson and John Olcott founded Olcott & McKesson on Maiden Lane in New York City in 1833 as a pharmaceutical wholesaler at a time when the American pharmaceutical industry barely existed. Their core function — aggregating drug supply from producers and delivering it to retail apothecaries — was structurally new and created a template for healthcare distribution that persists 190 years later. The company expanded from botanical drug importation into chemical pharmaceuticals in the 1850s and continued to grow through consolidation of regional drug wholesalers throughout the late 19th and early 20th centuries. It went public in 1989 to fund its expanding distribution footprint. Two strategic pivots in the 21st century define the modern company: the 2001 acquisition of RelayHealth for pharmacy connectivity technology, and the 2013 Change Healthcare joint venture with CVS Health for claims management. By FY2024 McKesson's revenue reached $308.9 billion — driven almost entirely by pharmaceutical distribution volume, where McKesson moves roughly one-third of all prescription drugs dispensed in the United States. That volume creates pricing leverage with manufacturers and operational scale that no new entrant could replicate.
McKesson, as the largest pharmaceutical distributor in the United States, became a central defendant in the opioid epidemic litigation. Distributors like McKesson were alleged to have failed in their legal obligation to identify and report suspicious orders of opioids to the DEA, and to have distributed quantities of oxycodone, hydrocodone, and similar controlled substances far exceeding what legitimate medical need could explain. In 2017, McKesson reached an initial settlement of $150 million with the DOJ over opioid distribution practices — at the time criticized as inadequate given the scale of the epidemic. In 2021, McKesson finalized a landmark $13.8 billion settlement spanning 18 years alongside AmerisourceBergen and Cardinal Health, with each of the three major distributors contributing approximately $4–5 billion. McKesson's share was approximately $7.4 billion to be paid over 18 years. The settlement represented a fundamental accountability moment for the distribution industry and required McKesson to invest in anti-diversion programs and independent monitoring. The company described the settlement as necessary to achieve finality and allow focus on core operations, though critics argued the payments were spread too widely across too many years to constitute real accountability.
McKesson formed a joint venture with Change Healthcare in 2013, combining its health IT assets with Change Healthcare's medical claims clearinghouse to create one of the largest healthcare IT infrastructure companies in the United States. McKesson held an approximately 70% stake. In January 2020, Change Healthcare went public via an IPO that valued the enterprise at approximately $7 billion. McKesson subsequently monetized portions of its stake, ultimately completing the full exit by 2022 and realizing proceeds used for share buybacks. The full acquisition noted in McKesson data (valued at $13.8 billion) reflects the total enterprise value attributed to the joint venture's assets at different points. Change Healthcare's claims clearinghouse processes over 15 billion healthcare transactions annually, representing approximately $2 trillion in claim value, and its connectivity to virtually every payer and provider in the U.S. creates infrastructure that competitors cannot easily duplicate. The 2024 Change Healthcare cyberattack — attributed to the ransomware group ALPHV/BlackCat after it was fully independent — disrupted U.S. healthcare payment processing, demonstrating how dependent the entire industry had become on this infrastructure.
McKesson acquired US Oncology in 2010 for $2.0 billion, gaining access to the largest network of community oncology practices in the United States. US Oncology managed the business operations, purchasing, and clinical research infrastructure for over 1,400 independent oncologists practicing in community settings — outside hospital systems. This acquisition positioned McKesson at the center of the community oncology supply chain: it could distribute chemotherapy agents, biosimilars, and supportive-care medications to these practices while providing the operational infrastructure they needed to remain independent from hospital acquisition. McKesson Specialty Health (which incorporates the US Oncology network) has become one of McKesson's highest-margin business segments because specialty pharmaceuticals — particularly oncology biologics — carry higher average selling prices than generic or commodity drugs, and the operational services provided to oncologists generate fee income beyond pure distribution. The community oncology channel is also strategically important because it handles an increasing share of cancer treatment that was historically done in hospital infusion centers, making McKesson's position in this network a long-term growth asset.
McKesson navigated the transformation of the American pharmaceutical industry across the 20th century by consistently adapting its distribution model to new product types. In the early 1900s, the introduction of synthetic drugs — aspirin, barbiturates, insulin — required different handling, storage, and quality standards than botanical preparations. McKesson invested in cold-chain capabilities for biologics and controlled-substance compliance infrastructure as regulation expanded. The 1938 Federal Food, Drug, and Cosmetic Act and subsequent amendments created a more complex regulatory environment that reinforced the wholesaler role: manufacturers increasingly preferred distributing through licensed, compliant wholesalers rather than managing direct distribution to thousands of pharmacies. The post-WWII antibiotic era created enormous prescription volume that expanded McKesson revenue. The 1950s–1970s saw the rise of pharmacy chains (Walgreens, CVS) that became major McKesson customers alongside independent pharmacies. McKesson grew through this era by acquiring regional drug wholesalers, steadily expanding its national footprint. By the time it went public in 1989, McKesson had become one of the largest distributors in the country through decades of quiet consolidation rather than a single transformative event.